Progressive Supranuclear Palsy Clinical Trial
Official title:
Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
The PET tracer [F18]-FDDNP has a specific affinity for lesions containing tau protein.
The study consists of two phases:
- In the first (cross-sectional) phase it will be assessed the uptake of [18F]-FDDNP in
10 cases with progressive supranuclear palsy (PSP, a tauopathy) en 10 with multi-system
atrophy (MSA, a non-tauopathy), along with 20 individuals with Unclassifiable
Parkinsonism, as previously defined in a European cohort study.
- In the second (longitudinal) phase it will be prospectively followed the 20
unclassifiable patients (at 6, 12 and 18 months) by means of validated scales and
accepted diagnostic criteria in order to try to correlate their eventual clinical
diagnosis with baseline PET findings. On this basis, we endeavour to estimate the
ability of this technique to detect in vivo underlying tau pathology in subjects
initially unclassifiable on clinical grounds.
We hypothesized that:
1. Patients with clinically definite PSP will present an increased uptake in basal
ganglia, brainstem and cerebellum.
2. Patients with clinically defined MSA will not present specific uptake.
3. Part of unclassifiable patients with parkinsonism will present a pattern of uptake
similar to patients with clinically defined PSP and this part along the clinical
follow-up will be meet clinical criteria for diagnose of PSP
n/a
Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04096651 -
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
|
N/A | |
| Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
| Completed |
NCT00703677 -
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00382824 -
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
|
N/A | |
| Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
| Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
| Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
| Recruiting |
NCT04139551 -
Oxford Study of Quantification in Parkinsonism
|
||
| Completed |
NCT02734485 -
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
|
N/A | |
| Completed |
NCT01110720 -
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
|
Phase 2/Phase 3 | |
| Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
| Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
| Completed |
NCT02460094 -
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
|
Phase 1 | |
| Active, not recruiting |
NCT04993768 -
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
|
Phase 2 | |
| Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
| Completed |
NCT03058965 -
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
|
Early Phase 1 | |
| Recruiting |
NCT02605785 -
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
|
N/A | |
| Completed |
NCT01353183 -
Analysis of the Enteric Nervous System Using Colonic Biopsies
|
N/A | |
| Completed |
NCT00385710 -
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
|
Phase 2 | |
| Recruiting |
NCT05260151 -
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
|